首页> 外文期刊>Pharmaceutical statistics. >A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials
【24h】

A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials

机译:两阶段试验中对样本量重新估计的群体顺序方法的回顾和重新解释

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In this paper, we review the adaptive design methodology of Li et al. (Biostatistics 3:277-287) for two-stage trials with mid-trial sample size adjustment. We argue that it is closer in principle to a group sequential design, in spite of its obvious adaptive element. Several extensions are proposed that aim to make it even more attractive and transparent alternative to a standard (fixed sample size) trial for funding bodies to consider. These enable a cap to be put on the maximum sample size and for the trial data to be analysed using standard methods at its conclusion. The regulatory view of trials incorporating unblinded sample size re-estimation is also discussed.
机译:在本文中,我们回顾了Li等人的自适应设计方法。 (Biostatistics 3:277-287)进行两阶段试验,并调整中期样本量。我们认为,尽管它具有明显的自适应元素,但从原理上讲它更接近于群体顺序设计。提出了几个扩展,旨在使其成为供资助机构考虑的标准(固定样本量)试验的更具吸引力和透明度的替代方案。这些可以使最大样本量达到上限,并在结论时使用标准方法分析试验数据。还讨论了结合无盲样本大小重新估计的试验的监管观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号